AZD8186, a potent and selective inhibitor of PI3Kβ/δ, as monotherapy and in combination with abiraterone acetate plus prednisone (AAP), in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)

J. S. de Bono, A. Hansen, A. D. Choudhury, N. Cook, E. I. Heath, C. Higano, M. Linch, J. Martin-Liberal, D. E. Rathkopf, K. B. Wisinski, S. Barry, E. de Bruin, W. Brugger, S. Colebrook, T. Klinowska, M. Moschetta, P. G.S. Mortimer, L. L. Siu, G. Shapiro

Research output: Contribution to conferenceAbstractpeer-review

Original languageEnglish
Publication statusPublished - 1 Oct 2018

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre

Cite this